Baseline characteristics of users of sodium-glucose cotransporter-2 inhibitors and other second-line to third-line drugs
| . | Sodium-glucose cotransporter-2 inhibitors (n = 14 409) . | Other second-line to third-line drugs (n = 43 620) . |
|---|---|---|
| Age in years, mean (SD) | 60.50 (9.93) | 64.97 (12.63) |
| Male, n (%) | 8799 (61.1) | 26 016 (59.6) |
| Smoking status, n (%) | ||
| Current | 2558 (17.8) | 8058 (18.5) |
| Past | 7221 (50.1) | 21 279 (48.8) |
| Never | 4615 (32.0) | 14 194 (32.5) |
| Unknown | 15 (0.1) | 89 (0.2) |
| BMI in kg/m2, n (%) | ||
| <30 | 3763 (26.1) | 19 099 (43.8) |
| ≥30 | 10 604 (73.6) | 24 153 (55.4) |
| Unknown | 42 (0.3) | 368 (0.8) |
| Haemoglobin A1c level, n (%) | ||
| ≤ 7.0 | 598 (4.2) | 3639 (8.3) |
| 7.1–8.0 | 2168 (15.0) | 9531 (21.9) |
| >8.0 | 11 562 (80.2) | 29 409 (67.4) |
| Unknown | 81 (0.6) | 1041 (2.4) |
| eGFR in mL/min, n (%) | ||
| >90 | 6943 (48.2) | 16 596 (38.2) |
| 60–90 | 6736 (46.7) | 17 923 (41.1) |
| 45–60 | 577 (4.0) | 4623 (10.6) |
| 30–45 | 93 (0.6) | 2989 (6.9) |
| 15–30 | 11 (0.1) | 927 (2.1) |
| <15 | 0 | 101 (0.2) |
| Unknown | 49 (0.3) | 461 (1.1) |
| Duration of diabetes in years, mean (SD) | 10.6 (5.0) | 8.0 (5.3) |
| Comorbidities, n (%) | ||
| Ischaemic heart disease including myocardial infarction | 2142 (14.9) | 7398 (17.0) |
| Heart failure | 337 (2.3) | 1490 (3.4) |
| Periphery arterial disease | 385 (2.7) | 1508 (3.5) |
| ICD/pacemaker | 92 (0.6) | 519 (1.2) |
| Hypertension | 8629 (59.9) | 25 880 (59.3) |
| Stroke | 754 (5.2) | 3393 (7.8) |
| Pharmacotherapy, n (%) | ||
| Beta-blockers | 3172 (22.0) | 10 167 (23.3) |
| Calcium channel blockers | 4313 (29.9) | 12 991 (29.8) |
| Diuretics | 3399 (23.6) | 11 895 (27.3) |
| Renin-angiotensin system inhibitors | 9709 (67.4) | 26 145 (59.9) |
| Statins | 11 369 (78.9) | 32 654 (74.9) |
| Nitrates | 910 (6.3) | 3168 (7.3) |
| Antiarrhythmic drugs | 11 (0.1) | 75 (0.2) |
| Anticoagulantia | 212 (1.5) | 897 (2.1) |
| Cardiovascular drugs, n (%) | ||
| 0 | 1247 (8.7) | 5055 (11.6) |
| 1 | 3017 (20.9) | 9216 (21.1) |
| 2 | 3995 (27.7) | 10 833 (24.8) |
| ≥3 | 6150 (42.7) | 18 516 (42.4) |
| Concomitant antidiabetic drug use | ||
| Metformin | 12 326 (85.5) | 36 990 (84.8) |
| Sulfonylureas | 8858 (61.5) | 28 864 (66.2) |
| Thiazolidinediones | 1262 (8.8) | 4346 (10.0) |
| GLP-1 analogues | 22 (0.2) | 227 (0.5) |
| DPP-4 inhibitors | 3794 (26.3) | 28 939 (66.3) |
| SGLT-2 inhibitors | 14 409 (100.0) | 0 |
| Insulin | 3237 (22.5) | 2784 (6.4) |
| Others | 73 (0.5) | 505 (1.2) |
| . | Sodium-glucose cotransporter-2 inhibitors (n = 14 409) . | Other second-line to third-line drugs (n = 43 620) . |
|---|---|---|
| Age in years, mean (SD) | 60.50 (9.93) | 64.97 (12.63) |
| Male, n (%) | 8799 (61.1) | 26 016 (59.6) |
| Smoking status, n (%) | ||
| Current | 2558 (17.8) | 8058 (18.5) |
| Past | 7221 (50.1) | 21 279 (48.8) |
| Never | 4615 (32.0) | 14 194 (32.5) |
| Unknown | 15 (0.1) | 89 (0.2) |
| BMI in kg/m2, n (%) | ||
| <30 | 3763 (26.1) | 19 099 (43.8) |
| ≥30 | 10 604 (73.6) | 24 153 (55.4) |
| Unknown | 42 (0.3) | 368 (0.8) |
| Haemoglobin A1c level, n (%) | ||
| ≤ 7.0 | 598 (4.2) | 3639 (8.3) |
| 7.1–8.0 | 2168 (15.0) | 9531 (21.9) |
| >8.0 | 11 562 (80.2) | 29 409 (67.4) |
| Unknown | 81 (0.6) | 1041 (2.4) |
| eGFR in mL/min, n (%) | ||
| >90 | 6943 (48.2) | 16 596 (38.2) |
| 60–90 | 6736 (46.7) | 17 923 (41.1) |
| 45–60 | 577 (4.0) | 4623 (10.6) |
| 30–45 | 93 (0.6) | 2989 (6.9) |
| 15–30 | 11 (0.1) | 927 (2.1) |
| <15 | 0 | 101 (0.2) |
| Unknown | 49 (0.3) | 461 (1.1) |
| Duration of diabetes in years, mean (SD) | 10.6 (5.0) | 8.0 (5.3) |
| Comorbidities, n (%) | ||
| Ischaemic heart disease including myocardial infarction | 2142 (14.9) | 7398 (17.0) |
| Heart failure | 337 (2.3) | 1490 (3.4) |
| Periphery arterial disease | 385 (2.7) | 1508 (3.5) |
| ICD/pacemaker | 92 (0.6) | 519 (1.2) |
| Hypertension | 8629 (59.9) | 25 880 (59.3) |
| Stroke | 754 (5.2) | 3393 (7.8) |
| Pharmacotherapy, n (%) | ||
| Beta-blockers | 3172 (22.0) | 10 167 (23.3) |
| Calcium channel blockers | 4313 (29.9) | 12 991 (29.8) |
| Diuretics | 3399 (23.6) | 11 895 (27.3) |
| Renin-angiotensin system inhibitors | 9709 (67.4) | 26 145 (59.9) |
| Statins | 11 369 (78.9) | 32 654 (74.9) |
| Nitrates | 910 (6.3) | 3168 (7.3) |
| Antiarrhythmic drugs | 11 (0.1) | 75 (0.2) |
| Anticoagulantia | 212 (1.5) | 897 (2.1) |
| Cardiovascular drugs, n (%) | ||
| 0 | 1247 (8.7) | 5055 (11.6) |
| 1 | 3017 (20.9) | 9216 (21.1) |
| 2 | 3995 (27.7) | 10 833 (24.8) |
| ≥3 | 6150 (42.7) | 18 516 (42.4) |
| Concomitant antidiabetic drug use | ||
| Metformin | 12 326 (85.5) | 36 990 (84.8) |
| Sulfonylureas | 8858 (61.5) | 28 864 (66.2) |
| Thiazolidinediones | 1262 (8.8) | 4346 (10.0) |
| GLP-1 analogues | 22 (0.2) | 227 (0.5) |
| DPP-4 inhibitors | 3794 (26.3) | 28 939 (66.3) |
| SGLT-2 inhibitors | 14 409 (100.0) | 0 |
| Insulin | 3237 (22.5) | 2784 (6.4) |
| Others | 73 (0.5) | 505 (1.2) |
Baseline characteristics of users of sodium-glucose cotransporter-2 inhibitors and other second-line to third-line drugs
| . | Sodium-glucose cotransporter-2 inhibitors (n = 14 409) . | Other second-line to third-line drugs (n = 43 620) . |
|---|---|---|
| Age in years, mean (SD) | 60.50 (9.93) | 64.97 (12.63) |
| Male, n (%) | 8799 (61.1) | 26 016 (59.6) |
| Smoking status, n (%) | ||
| Current | 2558 (17.8) | 8058 (18.5) |
| Past | 7221 (50.1) | 21 279 (48.8) |
| Never | 4615 (32.0) | 14 194 (32.5) |
| Unknown | 15 (0.1) | 89 (0.2) |
| BMI in kg/m2, n (%) | ||
| <30 | 3763 (26.1) | 19 099 (43.8) |
| ≥30 | 10 604 (73.6) | 24 153 (55.4) |
| Unknown | 42 (0.3) | 368 (0.8) |
| Haemoglobin A1c level, n (%) | ||
| ≤ 7.0 | 598 (4.2) | 3639 (8.3) |
| 7.1–8.0 | 2168 (15.0) | 9531 (21.9) |
| >8.0 | 11 562 (80.2) | 29 409 (67.4) |
| Unknown | 81 (0.6) | 1041 (2.4) |
| eGFR in mL/min, n (%) | ||
| >90 | 6943 (48.2) | 16 596 (38.2) |
| 60–90 | 6736 (46.7) | 17 923 (41.1) |
| 45–60 | 577 (4.0) | 4623 (10.6) |
| 30–45 | 93 (0.6) | 2989 (6.9) |
| 15–30 | 11 (0.1) | 927 (2.1) |
| <15 | 0 | 101 (0.2) |
| Unknown | 49 (0.3) | 461 (1.1) |
| Duration of diabetes in years, mean (SD) | 10.6 (5.0) | 8.0 (5.3) |
| Comorbidities, n (%) | ||
| Ischaemic heart disease including myocardial infarction | 2142 (14.9) | 7398 (17.0) |
| Heart failure | 337 (2.3) | 1490 (3.4) |
| Periphery arterial disease | 385 (2.7) | 1508 (3.5) |
| ICD/pacemaker | 92 (0.6) | 519 (1.2) |
| Hypertension | 8629 (59.9) | 25 880 (59.3) |
| Stroke | 754 (5.2) | 3393 (7.8) |
| Pharmacotherapy, n (%) | ||
| Beta-blockers | 3172 (22.0) | 10 167 (23.3) |
| Calcium channel blockers | 4313 (29.9) | 12 991 (29.8) |
| Diuretics | 3399 (23.6) | 11 895 (27.3) |
| Renin-angiotensin system inhibitors | 9709 (67.4) | 26 145 (59.9) |
| Statins | 11 369 (78.9) | 32 654 (74.9) |
| Nitrates | 910 (6.3) | 3168 (7.3) |
| Antiarrhythmic drugs | 11 (0.1) | 75 (0.2) |
| Anticoagulantia | 212 (1.5) | 897 (2.1) |
| Cardiovascular drugs, n (%) | ||
| 0 | 1247 (8.7) | 5055 (11.6) |
| 1 | 3017 (20.9) | 9216 (21.1) |
| 2 | 3995 (27.7) | 10 833 (24.8) |
| ≥3 | 6150 (42.7) | 18 516 (42.4) |
| Concomitant antidiabetic drug use | ||
| Metformin | 12 326 (85.5) | 36 990 (84.8) |
| Sulfonylureas | 8858 (61.5) | 28 864 (66.2) |
| Thiazolidinediones | 1262 (8.8) | 4346 (10.0) |
| GLP-1 analogues | 22 (0.2) | 227 (0.5) |
| DPP-4 inhibitors | 3794 (26.3) | 28 939 (66.3) |
| SGLT-2 inhibitors | 14 409 (100.0) | 0 |
| Insulin | 3237 (22.5) | 2784 (6.4) |
| Others | 73 (0.5) | 505 (1.2) |
| . | Sodium-glucose cotransporter-2 inhibitors (n = 14 409) . | Other second-line to third-line drugs (n = 43 620) . |
|---|---|---|
| Age in years, mean (SD) | 60.50 (9.93) | 64.97 (12.63) |
| Male, n (%) | 8799 (61.1) | 26 016 (59.6) |
| Smoking status, n (%) | ||
| Current | 2558 (17.8) | 8058 (18.5) |
| Past | 7221 (50.1) | 21 279 (48.8) |
| Never | 4615 (32.0) | 14 194 (32.5) |
| Unknown | 15 (0.1) | 89 (0.2) |
| BMI in kg/m2, n (%) | ||
| <30 | 3763 (26.1) | 19 099 (43.8) |
| ≥30 | 10 604 (73.6) | 24 153 (55.4) |
| Unknown | 42 (0.3) | 368 (0.8) |
| Haemoglobin A1c level, n (%) | ||
| ≤ 7.0 | 598 (4.2) | 3639 (8.3) |
| 7.1–8.0 | 2168 (15.0) | 9531 (21.9) |
| >8.0 | 11 562 (80.2) | 29 409 (67.4) |
| Unknown | 81 (0.6) | 1041 (2.4) |
| eGFR in mL/min, n (%) | ||
| >90 | 6943 (48.2) | 16 596 (38.2) |
| 60–90 | 6736 (46.7) | 17 923 (41.1) |
| 45–60 | 577 (4.0) | 4623 (10.6) |
| 30–45 | 93 (0.6) | 2989 (6.9) |
| 15–30 | 11 (0.1) | 927 (2.1) |
| <15 | 0 | 101 (0.2) |
| Unknown | 49 (0.3) | 461 (1.1) |
| Duration of diabetes in years, mean (SD) | 10.6 (5.0) | 8.0 (5.3) |
| Comorbidities, n (%) | ||
| Ischaemic heart disease including myocardial infarction | 2142 (14.9) | 7398 (17.0) |
| Heart failure | 337 (2.3) | 1490 (3.4) |
| Periphery arterial disease | 385 (2.7) | 1508 (3.5) |
| ICD/pacemaker | 92 (0.6) | 519 (1.2) |
| Hypertension | 8629 (59.9) | 25 880 (59.3) |
| Stroke | 754 (5.2) | 3393 (7.8) |
| Pharmacotherapy, n (%) | ||
| Beta-blockers | 3172 (22.0) | 10 167 (23.3) |
| Calcium channel blockers | 4313 (29.9) | 12 991 (29.8) |
| Diuretics | 3399 (23.6) | 11 895 (27.3) |
| Renin-angiotensin system inhibitors | 9709 (67.4) | 26 145 (59.9) |
| Statins | 11 369 (78.9) | 32 654 (74.9) |
| Nitrates | 910 (6.3) | 3168 (7.3) |
| Antiarrhythmic drugs | 11 (0.1) | 75 (0.2) |
| Anticoagulantia | 212 (1.5) | 897 (2.1) |
| Cardiovascular drugs, n (%) | ||
| 0 | 1247 (8.7) | 5055 (11.6) |
| 1 | 3017 (20.9) | 9216 (21.1) |
| 2 | 3995 (27.7) | 10 833 (24.8) |
| ≥3 | 6150 (42.7) | 18 516 (42.4) |
| Concomitant antidiabetic drug use | ||
| Metformin | 12 326 (85.5) | 36 990 (84.8) |
| Sulfonylureas | 8858 (61.5) | 28 864 (66.2) |
| Thiazolidinediones | 1262 (8.8) | 4346 (10.0) |
| GLP-1 analogues | 22 (0.2) | 227 (0.5) |
| DPP-4 inhibitors | 3794 (26.3) | 28 939 (66.3) |
| SGLT-2 inhibitors | 14 409 (100.0) | 0 |
| Insulin | 3237 (22.5) | 2784 (6.4) |
| Others | 73 (0.5) | 505 (1.2) |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
